Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Helle

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Optics Express|July 16, 2021
Study of waveguide background at visible wavelengths for on-chip nanoscopyDavid A Coucheron, Øystein I Helle, James S Wilkinson, et al.
The Prostate|October 1, 2019
Impact of positive surgical margins on secondary treatment, palliative radiotherapy and prostate cancer-specific mortality. A population-based study of 13 198 patientsRune Kvåle, Tor Å Myklebust, Sophie D Fosså, et al.
British Journal of Cancer|July 14, 1998
Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I studyS I Helle, J Geisler, J P Poulsen, et al.
Clinical Endocrinology|January 1, 1995
Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patientsP E Lønning, S I Helle, D C Johannessen, et al.
The Lancet. Oncology|December 3, 2014
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trialPeter Hoskin, Oliver Sartor, Joe M O'Sullivan, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2005
Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapyS I Helle, W Mietlowski, J P Guastalla, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2017
An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223O Sartor, R E Coleman, S Nilsson, et al.
The Lancet. Oncology|May 20, 2014
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trialOliver Sartor, Robert Coleman, Sten Nilsson, et al.
European Urology|July 15, 2017
Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer TrialChristopher C Parker, Robert E Coleman, Oliver Sartor, et al.
The New England Journal of Medicine|July 19, 2013
Alpha emitter radium-223 and survival in metastatic prostate cancerC Parker, S Nilsson, D Heinrich, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Optics Express|July 16, 2021
Study of waveguide background at visible wavelengths for on-chip nanoscopyDavid A Coucheron, Øystein I Helle, James S Wilkinson, et al.
The Prostate|October 1, 2019
Impact of positive surgical margins on secondary treatment, palliative radiotherapy and prostate cancer-specific mortality. A population-based study of 13 198 patientsRune Kvåle, Tor Å Myklebust, Sophie D Fosså, et al.
British Journal of Cancer|July 14, 1998
Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I studyS I Helle, J Geisler, J P Poulsen, et al.
Clinical Endocrinology|January 1, 1995
Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patientsP E Lønning, S I Helle, D C Johannessen, et al.
The Lancet. Oncology|December 3, 2014
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trialPeter Hoskin, Oliver Sartor, Joe M O'Sullivan, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2005
Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapyS I Helle, W Mietlowski, J P Guastalla, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2017
An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223O Sartor, R E Coleman, S Nilsson, et al.
The Lancet. Oncology|May 20, 2014
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trialOliver Sartor, Robert Coleman, Sten Nilsson, et al.
European Urology|July 15, 2017
Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer TrialChristopher C Parker, Robert E Coleman, Oliver Sartor, et al.
The New England Journal of Medicine|July 19, 2013
Alpha emitter radium-223 and survival in metastatic prostate cancerC Parker, S Nilsson, D Heinrich, et al.
Pageof 4